Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- The People's Hospital of Leshan
- Target Recruit Count
- 34
- Registration Number
- NCT03393507
- Locations
- 🇨🇳
Zhang xuan, Leshan, Sichuan, China
A Study of Apatinib in Recurrent or Recurrent High-grade Glioma
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03390062
Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 144
- Registration Number
- NCT03389256
- Locations
- 🇨🇳
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
🇨🇳Sichuan Cancer Hospital, Chengdu, Sichuan, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
- Conditions
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 38
- Registration Number
- NCT03384511
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03383237
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Zhengzhou University
- Target Recruit Count
- 32
- Registration Number
- NCT03376958
- Locations
- 🇨🇳
Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03376737
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Apatinib in Advanced Non-squamous，NSCLC
- Conditions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Jian Fang
- Target Recruit Count
- 100
- Registration Number
- NCT03376191
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer
- First Posted Date
- 2017-12-07
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT03365765
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, China
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT03359018
- Locations
- 🇨🇳
Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.